Mobile

A 26-week extension to a 26-week treatment, multicenter, randomized, double-blind, placebo-controlled, adaptive, seamless, parallel-group study to assess safety, tolerability and efficacy of two do...

Mise à jour : Il y a 5 ans
Référence : EUCTR2008-000663-42

A 26-week extension to a 26-week treatment, multicenter, randomized, double-blind, placebo-controlled, adaptive, seamless, parallel-group study to assess safety, tolerability and efficacy of two doses of indacaterol (150 and 300 μg o.d.) in patients with chronic obstructive pulmonary disease

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the safety of two indacaterol doses (150 and 300 μg o.d. via SDDPI) in patients with moderate to severe COPD as compared to placebo after 52 weeks of treatment.

Critère d'inclusion

  • BPCO

Liens